Height Outcome of Recombinant Human Growth Hormone Treatment in Achondroplasia Children: A Meta-Analysis.

Abstract

BACKGROUND/AIMS:

Although recombinant human growth hormone (rhGH) is not approved to treat short stature of achondroplasia (ACH), some studies suggested growth improvement during short-term rhGH treatment.

METHODS:

A meta-analysis of rhGH therapy efficacy in ACH children was performed.

RESULTS:

From 12 English-language studies, 558 (54.0% males) rhGH-treated ACH children were enrolled. Administration of rhGH (median dosage 0.21 mg/kg/ week; range 0.16-0.42 mg/kg/week) improved height (Ht) from baseline [-5.069 standard deviation score (SDS; 95% CI -5.109 to -5.029); p < 0.0001] to 12 [-4.325 SDS (95% CI -4.363 to -4.287); p < 0.0001] and 24 months [-4.073 SDS (95% CI -4.128 to -4.019); p < 0.0001]. Then, Ht remained approximately constant up to 5 years [-3.941 SDS (95% CI -4.671 to -3.212); p < 0.0001].

CONCLUSIONS:

In ACH children, rhGH treatment increased Ht from -5.0 to -4.0 SDS during 5 years, but insufficient data are available on both the adult Ht and the changes of body proportions.

• Authors: Mario Miccoli, Silvano Bertelloni, Francesco Massart
• Journal: Hormone research in paediatrics (Horm Res Paediatr) Vol. 86 Issue 1 Pg. 27-34 ( 2016) ISSN: 1663-2826 [Electronic] Switzerland
• PMID: 27355624 (Publication Type: Journal Article, Meta-Analysis, Review)
• Copyright: © 2016 S. Karger AG, Basel.

Chemical References

• Human Growth Hormone

Topics

• Achondroplasia (drug therapy, physiopathology)
• Adolescent
• Adult
• Body Height (drug effects)
• Child
• Child, Preschool
• Female
• Human Growth Hormone (therapeutic use)
• Humans
• Infant
• Male